Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Non-invasive characterization of intratumoral CD8+ T cells using standard-of-care (SOC) CT and ⁸⁹Zr-crefmirlimab berdoxam PET (CD8-PET) radiomic signature in solid tumors.

Jayant Narang, Ozlem Yardibi, Ron Korn et al. Jun 01, 2026 pp. 2614-2614 10.1200/jco.2026.44.16_suppl.2614

2614 Background: Noninvasive estimation of intratumoral CD8+ T-cell density using radiomics may enhance comprehensive immu...

Reproductive and pregnancy-related outcomes among adolescent and young adult female cancer survivors (15–39 years): A nationwide population-based study in South Korea.

Ja Yoon Heo, Jisun Yoon, Ju Hyun Jin et al. Jun 01, 2026 pp. 12104-12104 10.1200/jco.2026.44.16_suppl.12104

12104 Background: As survival rates among adolescent and young adult (AYA) female cancer patients improve, increasing numb...

Trends and burden of retinoblastoma incidence, prevalence, and mortality in the United States, 1990–2023: A retrospective analysis with machine learning projections to 2050.

Anika Chowdhury, Ibrahim Khalil, Sunjida Amin Promi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22609

e22609 Background: Retinoblastoma, a rare intraocular malignancy primarily affecting children, has seen declining age-stan...

Efficacy and safety of engineered TCR-T cell therapy (afami-cel, lete-cel) in pediatric synovial sarcoma.

Amy E. Armstrong, Veronique Minard-Colin, John Glod et al. Jun 01, 2026 pp. 11569-11569 10.1200/jco.2026.44.16_suppl.11569

11569 Background: Synovial sarcoma (SyS) represents ~ 5% of adult soft tissue sarcomas, however, SyS is the most common no...

Inflammatory markers as predictors of pathological complete response in patients with breast cancer after neoadjuvant chemotherapy.

Carolina Feitosa Leal Nunes, Laís Albernaz Kury, Walquiria Sayuri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12653

e12653 Background: Breast cancer is the most common cancer and the leading cause of cancer-related death in women. Patholo...

Integrated AI-informed morphologic and spatial transcriptomics features from H&E slides to enable risk stratification of primary melanoma patients.

Bhakti Vilas Baheti, Rishab Anand, Amritpal Singh et al. Jun 01, 2026 pp. 9559-9559 10.1200/jco.2026.44.16_suppl.9559

9559 Background: Tumor proliferative activity and the tumor-stroma microenvironment are key determinants of melanoma aggre...

Barriers to integrating obesity management into cancer survivorship care: Results from a single-institution survey.

Jaleesa Akuoko, Melissa Louise Pilewskie, Lesly Ann Dossett et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13783

e13783 Background: Cancer survivors with obesity are at increased risk of cancer recurrence, cancer-related mortality, and...

Prospective evaluation of AI-assisted documentation and summarization in virtual multidisciplinary cancer conferences.

Luxiga Thanabalachandran, Fabio Ynoe de Moraes, Darya Ali et al. Jun 01, 2026 pp. 1614-1614 10.1200/jco.2026.44.16_suppl.1614

1614 Background: Multidisciplinary cancer conferences (MCCs) are central to high-quality oncologic decision-making but are...

Rare germline heterozygous pathogenic BLM variants and correlations with co-occurring pathogenic variants and severe treatment-related adverse events in breast cancer.

Wei Lu, Riqing Huang, Yanxia Shi Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12603

e12603 Background: The BLM gene encodes a RecQ family DNA helicase. Biallelic pathogenic mutations in BLM cause Bloom synd...

Tele-nutritional collaborative care in patients with stage IV gastrointestinal cancer receiving chemotherapy: A randomized clinical trial.

Shihong Xu, Jitao Zhou, Tingting Dai et al. Jun 01, 2026 pp. 12043-12043 10.1200/jco.2026.44.16_suppl.12043

12043 Background: Cancer cachexia is characterized by systemic inflammation and progressive muscle loss, fundamentally com...

RP2 oncolytic immunotherapy alone and in combination with nivolumab (nivo) in patients with advanced solid tumors: Final safety, efficacy, and biomarker results from the phase 1 first-in-human (FIH) study.

Joseph J. Sacco, Kevin Joseph Harrington, Andres Cervantes et al. Jun 01, 2026 pp. 2504-2504 10.1200/jco.2026.44.16_suppl.2504

2504 Background: RP2 is an HSV-1-based oncolytic immunotherapy expressing a fusogenic glycoprotein (GALV-GP-R...

High-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed seminoma: A single-center cohort.

Zachary Scott Meyer, Towfik Sebai, Sandra K. Althouse et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17013

e17013 Background: The optimal salvage therapy for patients with relapsed seminoma remains unsettled. We evaluated clinica...

Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia.

Rafael Madero Marroquin, Rebecca Abraham, Anand Ashwin Patel et al. Jun 01, 2026 pp. 6547-6547 10.1200/jco.2026.44.16_suppl.6547

6547 Background: We and others have reported the antileukemic activity of a 10-day regimen of the hypomethylating agent (H...

Efficacy and safety by tumor location in the phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) with gemcitabine/nab-paclitaxel in locally advanced pancreatic adenocarcinoma.

Fernando Rivera, Inmaculada Ales Diaz, Emil Lou et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16367

e16367 Background: Outcomes of unresectable, locally advanced pancreatic adenocarcinoma (LAPAC) remain poor, with therapy...

Systematic evaluation of machine learning optimization strategies for uveal melanoma detection using ultra-widefield photography.

Sanjay Ganesh, Virginia Tasso, Reem Abdulhameed Alahmadi et al. Jun 01, 2026 pp. 9560-9560 10.1200/jco.2026.44.16_suppl.9560

9560 Background: Early differentiation of uveal melanoma (UM) from benign intraocular lesions remains clinically challengi...

Multi-modal molecular profiling of CDH1 and CLDN18.2 to identify predictive biomarkers for zolbetuximab efficacy in patients with advanced gastric adenocarcinoma: The ZOL-C3 study.

Shuhei Suzuki, Yuka Kobayashi, Takanobu Kabasawa et al. Jun 01, 2026 pp. 3148-3148 10.1200/jco.2026.44.16_suppl.3148

3148 Background: Zolbetuximab is a chimeric monoclonal antibody designed to bind to claudin 18.2 (CLDN18.2) and induce ant...

Mutational signatures as potential predictors of HIPEC response and recurrence in ovarian cancer.

Thanh Hue Dellinger, Brad Nakamura, Nora Ruel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17577

e17577 Background: While Hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated overall survival benefit in ad...

Temporal trends in intensive care unit outcomes for lung cancer patients: A 15-year analysis of the MIMIC-IV database.

Shankar Biswas, Yashasvi Srivastava, Elangovan Krishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20693

e20693 Background: Lung cancer care has been transformed over the past decade. Targeted therapies and immunotherapy have e...

Effects of genome-wide modifiers of response to next-generation FGFR inhibitors in solid tumors—An Indian multicentric study.

Chirantan Bose, Vidya H. Veldore, Dr Anjali Kulkarni et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23422

e23422 Background: FGFR alterations are established actionable drivers in solid tumors, with particular clinical relevance...

Efficacy of immunotherapy-based regimens in Russian patients with <i>EGFR</i> -mutated metastatic NSCLC after EGFR TKI failure: A multi-institution real-world analysis.

Sergei Smolin, Lyudmila Zhukova, Fedor Vladimirovich Moiseenko et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20628

e20628 Background: Patients with EGFR-mutated (EGFRm) metastatic non-small cell lung cancer (mNSCLC) generally derive limi...

Myelodysplasia-related mutation dynamics and outcomes in newly diagnosed (ND) acute myeloid leukemia (AML) treated with low-intensity therapy (LIT).

Naszrin Arani, Sanam Loghavi, Courtney Denton DiNardo et al. Jun 01, 2026 pp. 6531-6531 10.1200/jco.2026.44.16_suppl.6531

6531 Background: Outcomes of patients (pts) with ND AML with myelodysplasia related gene mutations (MRMs), while tradition...

Outcomes following CAR-T therapy in adults with relapsed/refractory B-ALL according to prior inotuzumab exposure.

Vladimir Petre, Oladayo Oyebanji, Michael Daunov Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18626

e18626 Background: Chimeric antigen receptor T-cell (CAR-T) therapy represents a novel approach to relapsed and refractory...

Women’s perceptions and preferences regarding liquid biopsy for breast cancer screening.

Emily Sargent, Ehsan Irajizad, Susan K. Peterson et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22548

e22548 Background: Liquid biopsy is a potential new noninvasive tool for cancer detection and may address barriers to curr...

Time-restricted eating and metformin (TEAM) in invasive breast cancer or DCIS: A randomized, phase IIb, window-of-opportunity presurgical trial.

Parijatham S. Thomas, Stefano Spinaci, Irene Maria Briata et al. Jun 01, 2026 pp. 10524-10524 10.1200/jco.2026.44.16_suppl.10524

10524 Background: Preclinical studies indicate that metformin administered during fasting synergizes with feeding–fasting...

Risk of checkpoint inhibitor pneumonitis associated with anti-angiogenic agents in non–small cell lung cancer: An integrated analysis of meta-analysis of randomized controlled trials, FAERS, and real-world data.

Yaping Guan, Yue Dong, Yuekai Zhang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24163

e24163 Background: Immunotherapy with immune checkpoint inhibitors (ICIs) and antiangiogenic treatment represent the stand...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page